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in Pregnant Women (ACHOIS) trial was designed
to assess whether treatment of gestational diabetes
improved health outcomes; it was not designed as a
screening trial. Populations vary as to the prevalence
of pregnant women who will have gestational dia-
betes mellitus; hence the number needed to screen
will need to be calculated for local populations.
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Treatment of HBeAg-Positive Hepatitis B 
with Peginterferon and Lamivudine
 
to the editor: 
 
Lau et al. (June 30 issue)
 
1
 
 studied
pegylated interferon for the treatment of hepatitis
B e antigen (HBeAg)-positive chronic hepatitis B.
Overall, HBeAg seroconversion was highest among
patients treated with pegylated interferon mono-
therapy, despite the more potent hepatitis B virus
(HBV) DNA suppression with lamivudine at 48
weeks. Although viral suppression and HBeAg
seroconversion are well correlated,
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 the degree of
viral suppression needed for seroconversion to oc-
cur is not well defined. With regard to this study,
it would be of interest to know what the degree of
HBV DNA suppression was among patients in
whom HBeAg or hepatitis B surface antigen sero-
conversion occurred, as a separate analysis. Knowl-
edge of statistically significant predictors of sero-
conversion at 48 weeks and at 72 weeks would also
be relevant. In addition, the characteristics of pa-
tients in whom seroreversion occurred between
week 48 and week 72 would be important to know.
With regard to tolerance of pegylated interfer-
on, nearly half the patients required dose modifica-
tion. Since HBeAg seroconversion is known to oc-
cur with pegylated interferon at lower doses,
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 it
would be helpful if Lau et al. would comment on
any effects of dose modification on seroconversion
rates, HBV DNA levels, or both.
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to the editor: 
 
The comparison made by Lau et al.
between peginterferon alfa-2a and lamivudine
monotherapy administered for a fixed time peri-
od of 48 weeks, regardless of the occurrence and
moment of seroconversion, does not make much
sense. Current guidelines recommend administra-
tion of lamivudine for a minimum of one year and
maintenance treatment for three to six months after
HBeAg seroconversion is confirmed, on two occa-
sions that are at least two months apart, in order to
reduce the rates of relapse after treatment and po-
tentially life-threatening flares.
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 The duration of
treatment reported in this trial is therefore subopti-
mal for the majority of patients treated with lamiv-
udine. It would have been more appropriate to con-
tinue lamivudine in patients who did not meet the
criteria of current guidelines at week 48.
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the author replies: 
 
As noted by Drs. Song and Raj-
vanshi, viral suppression has been correlated with
HBeAg seroconversion. Among patients receiving
peginterferon alfa-2a monotherapy in our study,
the mean HBV DNA levels were reduced by 5.3 log
copies between baseline and 24 weeks after treat-
ment (week 72 overall) among patients with HBeAg
seroconversion as compared with 0.8 log copies
among patients without seroconversion. However,
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response rates at week 72 were significantly higher
with peginterferon alfa-2a than with lamivudine
among patients who had identical HBV DNA levels
at the end of the 48-week treatment period (Fig. 1).
This result suggests that the immunomodulatory
activity of peginterferon alfa-2a plays an important
role in improving sustained responses as com-
pared with lamivudine. For all treatment groups,
multivariate analysis identified baseline levels of
alanine aminotransferase, HBV DNA, and HBeAg
as significant predictors of HBeAg seroconversion
at week 72. Despite the high number of dose mod-
ifications reported, 78 percent of the patients treat-
ed with peginterferon alfa-2a monotherapy received
90 percent or more of the total dose. The rates of
HBeAg seroconversion were 28 percent and 33 per-
cent among patients receiving less than 90 percent
and 90 percent or more of the total dose, respec-
tively.
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Although Dr. Orlent’s comments on current
recommendations for lamivudine treatment are
accurate, insurance policies in some parts of the
world where the study was conducted still support
only a limited duration of lamivudine treatment
(Liaw YF: personal communication). This has high-
lighted the clinical problems associated with stop-
ping lamivudine, such as seroreversion, virologic
relapse, alanine aminotransferase flares, and even
hepatic decompensation, which are of major con-
cern when nucleoside or nucleotide analogue ther-
apy is used for the treatment of chronic hepatitis
B.
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 Even with prolonged lamivudine therapy, the
rates of HBeAg seroconversion increase by only 1 to
7 percent per year after the first year of treatment,
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which is in line with the spontaneous seroconver-
sion rate. Only after five years of lamivudine treat-
ment did the rates of HBeAg seroconversion reach
levels (35 percent)
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 that compare favorably with
those achieved in our study after one year of peg-
interferon alfa-2a treatment and six months of fol-
low-up (32 percent). Moreover, prolonged therapy
with lamivudine will increase the incidence of re-
sistance to lamivudine related to mutations of the
tyrosine, methionine, aspartate,
 
 
 
and aspartate mo-
tif, which is associated with potentially life-threat-
ening disease exacerbations.
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Figure 1. Response Rates at Week 72 among Patients Who Had HBV DNA 
Levels of Less Than 400 Copies per Milliliter at the End of 48 Weeks of Treat-
ment with Peginterferon Alfa-2a or Lamivudine.
 
The numbers within each bar are the numbers of patients with the level 
in question and the total number in the group. The numbers above the bars 
are the percentages of patients with a response.
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